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Abstract. In its role as a pineal hormone, melatonin is
a pleiotropic, nocturnally peaking and systemically
acting chronobiotic. These effects are largely ex-
plained by actions via G protein-coupled membrane
receptors found in the suprachiasmatic nucleus, but
also in numerous other sites. Nuclear (ROR/RZR),
cytoplasmic (quinone reductase-2, calmodulin, calre-
ticulin) and mitochondrial binding sites and radical-
scavenging properties contribute to the actions of
melatonin. Regulation of pineal melatonin biosyn-
thesis is largely explained by control mechanisms
acting on arylalkylamine N-acetyltransferase, at the
levels of gene expression and/or enzyme stability
influenced by phosphorylation and interaction with
14-3-3 proteins.Melatonin is not only a hormone but is
also synthesized in numerous extrapineal sites, in
which it sometimes attains much higher quantities
than in the pineal and the circulation. It is also present
in many taxonomically distant groups of organisms,
including bacteria, fungi, and plants. Moreover, mel-
atonin is a source of bioactive metabolites, such as 5-
methoxytryptamine, N1-acetyl-N2-formyl-5-methoxy-
kynuramine and N1-acetyl-5-methoxykynuramine.
Keywords. AFMK, AMK, cinnoline, indoleamine, melatonin-binding site, 5-methoxytryptamine, nitric oxide,
pineal gland.
Introduction
Melatonin was discovered as a pineal hormone, which
lightens skin of fish and amphibia by concentrating
mobile melanosomes of melanocytes (melanophores)
involved in physiological color change [1]. Even this
frequently cited observation fromapioneeringwork is
not without exception. In pencil fish, melanocytes
showed area-specific melanosome concentration or
dispersion [2]. Therefore, melatonin is not just anoth-
er example of the various skin-lightening hormones
present in several animal taxa, but rather transmits
signals eliciting different site-specific responses. This
view was confirmed by the discovery of high-ampli-
tude circadian melatonin rhythms in the pineal gland
and the circulation with prominent nocturnal peaks,
which were suppressed by light [3–7]. The chrono-
biological roles of melatonin as a mediator of dark
signals regulating both circadian oscillators and sea-
sonality have been reviewed many times and would
exceed the frame of this article.
Meanwhile, melatonin has turned out to be a ubiq-
uitous compound, detected in allmajor taxa studied so
far, including bacteria, dinoflagellates and other
eukaryotic protists, macroalgae, plants, fungi, and
various groups of invertebrate animals [for details see
refs 8–10]. In brief, the following lessons can be
deduced from these findings: (i) melatonin is not
generally associated with darkness, but can sometimes
also be elevated during photophase; (ii) in some
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species, it may even be arrhythmic; (iii) where it is
found to exhibit circadian oscillations, these are not
necessarily implicated in seasonality; (iv) in plants,
morphogenetic and photoprotective actionsmay be of
importance; (v) the concentrations of non-vertebrate
melatonin can vary extremely between species or taxa
and sometimes attain values in the upper micromolar
range. Therefore, melatonin can no longer be seen
solely as a trace compound, nor generally as a
hormone, and its functions have to be highly divergent
in the various organisms.
Although this indoleamine has been perceived for
decades in a mainly chronobiological context, even
vertebrate melatonin is not exclusively a hormone
present in only minute quantities and acting via the G
protein-coupled membrane receptors MT1 and MT2.
High-amplitude circadian oscillations, which mediate
the signal darkness, are not generally found. Tissue
melatonin enters the circulation poorly is and thus
only partially removed by hepatic first-pass metabo-
lism and not quantitatively excreted as 6-sulfatoxy-
melatonin. Therefore, the role as a mediator of the
signal darkness only reflects a part of the wider
spectrum of actions, presence, dynamics and metab-
olism exhibited by this remarkably pleiotropic and
ubiquitous indoleamine. This review will deal with
both the considerable progressmade in understanding
the cell biology of the classic functions of melatonin
and its roles beyond them.
Extrapineal melatonin: remarkable quantities and
non-classic roles
Extrapineal melatonin is somehow reminiscent of
cosmological dark matter. There is by far more
melatonin outside than inside the pineal gland and
circulation, but its extrapineal functions are poorly
understood, whereas the hormone secreted by the
pineal gland and its transmission of dark signals is part
of general knowledge and awareness. The much
higher quantities of extrapineal melatonin are fre-
quently not perceived by researchers or are consid-
ered irrelevant. However, extrapineal melatonin will
substantially widen our understanding of the numer-
ous roles of this molecule.
Pineal melatonin is formed from serotonin by two
steps catalyzed by arylalkylamineN-acetyltransferase
(AA-NAT) and hydroxyindole O-methyltransferase
(HIOMT) [6, 7]. In extrapineal sites and outside
vertebrates, other enzymes can be involved and
regulation mechanisms may be different. Extrapineal
melatonin synthesis has been identified, e,g. in the
retina [11–13], the Harderian gland [14–16] and later
in the parietal organ of reptiles [17]. At first glance,
retina and parietal organ, also being extrusions of the
intermediate brain, may appear as variants of the
same theme known from the pineal gland. They can
likewise generate robust, nocturnally peaking circa-
dian rhythms. However, with the exception of am-
phibian and some avian retinas, melatonin is only
poorly released from these organs. Consequently,
melatonin serves additional functions and is not only
acting as a hormone. Retinal melatonin efficiently
downregulates dopamine formation and release [11,
13]. Despite the similar rhythmicities of pineal and
retinal melatonin, their regulation can be entirely
different.Whilemelatonin in themammalian pineal is
largely regulated by norepinephrine of sympathetic
origin, retinal melatonin biosynthesis is stimulated via
GABAA and, partially, GABAB receptors [13]. The
light-dependent decrease of retinal melatonin is
caused by dopamine via D1 or D4 receptors [18].
Differences in metabolism exist, too, because retinal
melatonin is largely degraded by deacetylation to 5-
methoxytryptamine (5-MT) [12, 19], a compound
which can be further converted to 5-methoxytrypto-
phol (5-ML) or 5-methoxyindoleacetic acid (5-
MIAA) [8, 10, 20]. In the retina, deacetylation to 5-
MT can be catalyzed by a specific melatonin deace-
tylase, but in other organs or organisms by less specific
aryl acylamidases (AAAs) or eserine-sensitive ace-
tylcholinesterase [20]. 5-MT is a bioactive compound
too [8, 10, 20] and may play a role of its own in the
retina. In cultured retinal cells, it reportedly prevented
the forskolin-induced rise in cyclic AMP, independ-
ently of the melatonin receptors [21]. Where not
released from an organ, melatonin cannot not be
degraded in the liver or appear as urinary 6-sulfatox-
ymelatonin. In the brain, substituted kynuramines
were identified as major metabolites [22].
While robust circadian rhythmicity is typical for
pineal, parietal and retina, this is not so with the
rodent Harderian gland. Diurnal changes are poorly
expressed or almost absent, except for a transient drop
after onset of light [14, 16]. Therefore,melatonin is not
always associated with darkness in vertebrates. Var-
iations of Harderian melatonin were observed within
sexual or seasonal cycles, but these are related to
changes in gonadosteroids [14, 23]. Thus, annual
fluctuations appear as a consequence rather than a
cause of reproductive cycles.
Melatonin biosynthesis has been reported, or as-
sumed, for various additional tissues and cells, and, in
most cases, a transmission of dark signals seems highly
unlikely or impossible. Circadian rhythms, if present,
frequently exhibit small amplitudes or are at the
borderline of detection. In the mammalian brain,
other sites ofmelatonin formationmay exist, although
the evidence is relatively weak to date, whereas more
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information exists on the synthesis of the precursor,N-
acetylserotonin (NAS). O-methylation of NAS is not
necessarily an action of HIOMT, as in pineal, retina
and Harderian gland, but can be alternately catalyzed
by less specific methyltransferases. Relatively high
concentrations (up to 0.7 mM) of melatonin in the
brain have been reported [24], a finding which would
be in favor of local melatonin synthesis in some areas.
Abundance and sites of formation of 5-hydroxylated
and 5-methoxylated indoles in the central nervous
system have been recently summarized [20].
Gastrointestinal melatonin has been reviewed several
times [e.g., 25–27]. The indoleamine is produced in
enterochromaffin cells, but circulating melatonin can
be additionally taken up from the blood. Although
concentrations remain moderate, the entire gastro-
intestinal tract contains, owing to its size, about 400–
500 times more melatonin than the pineal gland [26,
27]. Its fate is complex, because the gut acts both as
source and sink. Uptake of circulating melatonin has
been studied by elevating its plasma level during
daytime to nighttime values [28]. Substantial amounts
were subsequently found unmetabolized in the intes-
tinal lumen [28]. This is in good agreement with high
quantities of melatonin in the bile fluid [29] and
enterohepatic cycling [29, 30]. Additionally, melato-
nin is taken up from food. Diurnal plasma levels were
increased by natural diets rich in melatonin, or
decreased by melatonin-depleted food [27, 31]. A
contribution of intestinal bacteria to melatonin in the
gut seems possible, but requires further investigation
[9]. Gastrointestinal melatonin can be released to the
circulation, in terms of a post-prandial response [26,
27], in particular, by elevated tryptophan [32]. Mel-
atonin surges elicited by this amino acid are consid-
erable in height, but of relatively short duration.
During daytime, they remain chronobiologically al-
most ineffective, since they appear in the silent zone of
the circadian phase-response curve [27]. Gastrointes-
tinal melatonin can also exhibit a circadian rhythmic-
ity of relatively low amplitude (maximum/minimum
2 :1) [27], which is sometimes barely detectable [26,
27].
Mammalian skin has been reported to be another site
of melatonin biosynthesis. The formation and pres-
ence of the enzymes required have been demonstrated
[33]. Serotonin N-acetylation is catalyzed by either
AA-NAT or by an arylamine N-acetyltransferase
subform [34]. An important and obviously unsettled
point concerns melatonin levels in vivo. Earlier
attempts to quantify this indoleamine in skin samples
by liquid chromatography failed to demonstrate
melatonin, and HIOMT activity remained below
detection levels [35], contrary to cultured HaCaT
keratinocytes, which contained very high amounts (ca
30 mMmelatonin, under consideration of an erratum)
[36]. A clarification of this discrepancy is urgently
required, to decide between dysregulation in cultured,
immortalized cells and inefficiency of safe extraction
from biopsies, as caused by oxidants in biological
material [9, 20].
Melatonin formation has been reported for several
other vertebrate tissues and cells, such as bonemarrow
[37] – along with assumptions concerning hemato-
poietic activity ofmelatonin [38] – and various types of
leukocytes [39, 40], platelets, erythrocytes and the
membranous cochlea [summarized in ref. 39]. Ele-
vated concentrations in other tissues [40, 41] may be
explained by uptake from the circulation. In some
cases, melatonin formation may result from inevitable
side reactions by unspecific N-acetyl and O-methyl-
transferases, e.g., in erythrocytes.
Regulation of melatonin biosynthesis
The classic pathway of melatonin formation involves
four steps, starting with tryptophan 5-hydroxylase,
followed by 5-hydroxytryptophan decarboxylation by
aromatic amino acid decarboxylase, N-acetylation of
serotonin by AA-NAT, andO-methylation of NAS by
HIOMT. Alternately, homologs or structurally differ-
ent N-acetyl- and O-methyltransferases can be in-
volved. In principle, the steps could also take place in
different sequential orders, e.g., serotonin ! 5-
MT ! melatonin, or 5-hydroxytryptophan ! 5-me-
thoxytryptophan ! 5-MT ! melatonin, but, in all
cases studied so far, the alternate sequences were of
minor importance. In organs or organisms which
deacetylate melatonin [42], re-acetylation of 5-MT
may be of some relevance [10]. In the classic pathway,
AA-NAT is usually believed to be the rate-limiting
enzyme, although tryptophan 5-hydroxylase can rep-
resent an additional control step, e.g., in amphibia.
Exceptions to this rule have been described. In
Drosophila, NAS concentrations are three orders of
magnitude higher than those of melatonin [43], and
thusO-methylation is limiting, a finding explained by
the loss of the HIOMT gene, so that methyl transfer
has to be catalyzed by other, presumably less specific
enzymes [20]. A functionally similar situation seems
to be present in the retinas of primates and ungulates,
in which HIOMT is not or poorly expressed at both
mRNA and protein levels [7]. Whether this leads to a
complete lack of retinally derivedmelatonin or only to
a reduction, remains to be clarified. In other mamma-
lian taxa, such as rodents, and in non-mammalian
vertebrates, HIOMT is sufficiently expressed in the
retina, and melatonin exhibits a nocturnally peaking
circadian rhythm. However, the rate limitation by
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AA-NAT was also disputed for the nocturnal rise of
melatonin in the rat pineal [44]. Because of nocturnal
NAS concentrations exceeding those of melatonin
and findings in a low-activity AA-NAT mutant
(H28Y), these investigators concluded that HIOMT
becomes rate-limiting at night.
The premier significance ofAA-NAT– recently called
the timezyme [7] – as the rate-limiting enzyme of
melatonin biosynthesis, e.g., in pinealocytes, deserves
an outline of its regulation. AA-NAT can be regulated
at different levels, that of gene expression and that of
enzyme activation and stability (Fig. 1). Which of
these mechanisms is responsible in a specific case, or
even both of them, depends on species and organ. Two
different types of control have to be distinguished,
which can complement each other under natural
conditions: (i) a circadian regulation, either via
components of the oscillator or by norepinephrine-
dependent rhythms of protein kinases, and (ii) a photic
turnoff mechanism. Transcriptional regulation is af-
forded by respective control elements in theAA-NAT
promoter, especially photoreceptor conserved ele-
ments (PCEs; RCS in Drosophila) [45, 46], which
respond to transcription factors of the CRX/OTX
family [46, 47], andE-boxes, which can be under direct
control of an oscillator, e.g. by binding of BMAL1/
CLOCKor, in humans, BMAL1/MOP4 heterodimers
[7, 48]. E-boxes can also be accessible to other
transcription factors or modulated by additional
control elements [48]. In mammalian pineals, calci-
um/cAMP response elements (CREs) can be involved
in sympathetic stimulation [7, 49–51].
Regulation at the level of the translated enzyme
protein comprises phosphorylation and interaction of
the phosphorylated AA-NAT with a 14-3-3 protein
(isoforms z or e). Both cAMP and Ca2+ signaling can
contribute to this mechanism, involving either protein
kinase A (PKA) [7, 51, 52] or protein kinase C (PKC)
[53]. Phosphorylation depends on N- and C-terminal
flanking regions, which are typical for the vertebrate
AA-NAT, but not found in homologs or paralogs of
urochordates, invertebrate animals or other organims
[7]. These regions contain PKA- and PKC-specific
motifs. The association of AA-NAT with a 14-3-3
protein (usually studied with subform z) results in
stabilization of the enzyme protein [7, 52]. Scaffolding
with 14-3-3 protein may also favor the stability of the
enzymes active center [7]. The stoichiometry of the
complex (one or twoAA-NATmolecules with one 14-
3-3z dimer) is still uncertain. It is of particular
functional significance that the stability of the com-
plex remains moderate, so that it regularly dissociates
and AA-NAT becomes accessible to protein phos-
phatases [52]. The dephosphorylated enzyme is prone
to rapid proteasomal degradation [7, 54]. The velocity
of this process can explain a rapid enzyme inactivation
observed upon exposure to nocturnal light, a major
component of the photic turnoff mechanism, which
may, however, be accompanied by a shutoff at the
level of gene transcription.
The twomechanisms of regulation, which act on either
gene expression or enzyme stability, are effective to a
different extent among species, and additional varia-
tions become apparent between melatonin-synthesiz-
ing organs. The AA-NAT phosphorylation/14-3-3
mechanism is present in all vertebrates, at least in
the pineal gland, whereas this cannot be the case in
non-vertebrate organisms which lack the N- and C-
terminal flanking regions [7]. Other post-translational
modifications and interactions with different proteins
thatmay shieldmodified amino acid residues have not
been studied outside the vertebrates. Data on tran-
scriptional control of non-vertebrate AA-NAT ho-
mologs or paralogs are largely missing (except of
processes related to cuticle formation), and the wide
distribution of N-acetyltransferases indicates other
functions not related to melatonin, but, e.g., to
sclerotization. Even within the mammals, fundamen-
tal differences exist, so that findings obtained in
rodents are not generally applicable to humans. In the
pineal gland of primates and ungulates, AA-NAT
seems to be only regulated by formation and decay of
the phospho-AA-NAT/14-3-3 complex [7], as far as is
known. This is sufficient for a considerable nocturnal
rise in active enzyme protein as well as the photic
shutoff taking place as soon as cAMP decreases and,
consequently, PKA activity. In rhesus monkeys, a 4-
fold nocturnal increase in AA-NAT activity was
observed, whereas its mRNAdid not show substantial
variations [7]. Similar findings were made in sheep
and cattle [7, 54]. However, rodents exhibit a rhythm
in pineal AA-NAT mRNA of remarkable amplitude,
with 100- or even 150-fold nocturnal rises [7, 49, 55,
56].
The rhythm of AA-NAT mRNA as well as an
additional shutoff mechanism at the expression level
have turned out to bemultifaceted phenomena, which
do not seem to be solely explained by the rate of
transcription, although this is, of course, an important
basis. Transcription is, again, subject to both positive
and negative control. Expression can be regulated
either directly by a circadian oscillator, via tran-
scription factors mentioned above, or indirectly via a
neuronal pathway which is typical for mammals, but
contributes to a certain extent also to the pineal
rhythm in birds. In the directly light-sensitive pineal
glands of non-mammalian species and in retinal
photoreceptors, an autonomous, primary circadian
oscillator is present in AA-NAT-expressing cells [7,
57, 58], so that this enzyme can be under direct control
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of the oscillator. In addition to transcription factors
that are part of the clockwork, the oscillator can also
regulate AA-NAT expression by modulating cAMP
levels, as shown for avian retinas [57, 58].
The mammalian pineal gland is controlled by the
suprachiasmatic nucleus (SCN), a hypothalamic struc-
ture acting as a circadian master clock. The photic
input ismediated via the retinohypothalamic tract, the
paraventricular nucleus and a sympathetic connection
from the intermediolateral cell column of the upper
thoracic cord to the superior cervical ganglion, which
innervates the pineal [59]. Norepinephrine released
from the post-ganglionic sympathetic fibers acts via
two signaling pathways, which complement and re-
inforce each other. Binding to b1-adrenergic receptors
leads to activation of adenylyl cyclase and, conse-
quently, PKA [7, 51, 55], whereas a concomitant
action via a1B-adrenergic receptors causes, via Go and
phospholipase Cb, a rise in Ca2+[i] , membrane trans-
location and activation of PKC [51, 53]. Moreover,
elevated cAMP and Ca2+[i] are thought to open Ca
2+
channels – although pineal L-channels were shown to
Figure1. Regulation of AA-
NAT expression and activity.
The scheme combines different
pathways which are not collec-
tively present in any one system.
Black arrows and lettering: path-
ways present in pineal glands of
many mammals; violet color:
pathways present in rodents, but
not (or not demonstrated) in
primates and ungulates; brown
color: pathways present in sys-
tems containing endogenous,
self-sustained oscillators (non-
mammalian systems and some
mammalian retinas). Pathways
of particular importance are em-
phasized by larger letters. AA-
NAT, arylalkylamine N-acetyl-
transferase; ai, as, aq, a subunits
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be shut by cAMPor adrenergic stimulation [60] – and
to further stimulate cAMP production via activated
CaM kinase [51], which can be additionally upregu-
lated via a1B-adrenergic signaling. Both b1- and a1B-
adrenergic effects jointly regulate the phosphoryla-
tion of AA-NAT and, thus, the stabilization by 14-3-
3z. In systems with transcriptional control, they also
stimulate AA-NATexpression by phosphorylation of
CREB (Ca2+/cAMP response element-binding pro-
tein), in particular, via PKA type II [7, 51, 61].
The adrenergic cAMP/Ca2+ regulatory system is
further modulated by several neuropeptides and
glutamate. Pituitary adenylyl cyclase-activating pep-
tide (PACAP), originating from a trigeminal innerva-
tion, and vasoactive intestinal peptide (VIP), from a
pterygopalatine connection, stimulate adenylyl cy-
clase via a common VPAC1 receptor [51, 60]. Inhib-
itory actions are mediated by neuropeptide Y (NPY)
from both sympathetic nerve endings and the inter-
geniculate leaflet, via Gi-coupled pinealocyte Y1 and
presynaptic Y2 receptors, and from intrapineal gluta-
mate via the metabotropic receptor mGlu3 [51].
Transcription of the Aa-nat gene, as induced by
phospho-CREB (pCREB), is subject to two kinds of
inhibition. The first represents a negative feedback
mechanism. pCREB also induces a truncated CREM
(CRE modulator) variant, ICER (inducible cAMP
early repressor), which interferes with pCREB bind-
ing to its response element [51, 55, 61]. Through this
mechanism, Aa-nat expression becomes temporally
limited. The other type of inhibition seems to be
specific for the photophase when pinealmelatonin has
to be suppressed. The transcription factors DREAM
[downstream regulatory element (DRE) antagonist
modulator] and the related KChIP (potassium chan-
nel-interacting protein) are capable of downregulat-
ing the expression of genes containing DRE in their
promoter, in particular Aa-nat, but also Icer [51, 62].
AA-NAT expression is not only controlled at the
transcriptional level, but in addition post-transcrip-
tionally by heterogeneous nuclear ribonucleoproteins,
hnRNPs R, Q and L. The effects of these proteins are
dual, depending on their binding sites. When binding
to loops in the 3’-untranslated region (3’UTR) region
of the rat AA-NATmRNA, all three of them strongly
favor mRNA degradation [56]. However binding of
hnRNPQ to the IRES motif (internal ribosome entry
site) in the 5’UTR region stimulates the rate of
translation [63]. In rat pineals, all three hnRNPs
exhibited robust circadian rhythms [56]. Levels of
hnRNP R and Q were shown to peak (maximum/
minimum ratio ca 2) around the maximum of pCREB
[zeitgeber time (ZT) 19], about 2 h after themaximum
of AA-NAT mRNA (ZT 17), whereas hnRNP L
expression was maximal 4 h later (ZT 21), with a
maximum/minimum ratio of 7 [56]. This indicates a
control of AA-NATmRNAdegradation especially by
hnRNP L. However, the physiological meaning of the
IRES-dependent translational upregulation by
hnRNP Q, which contrasts with the negative effect
on mRNA stability, requires further elucidation.
Melatoninergic actions via membrane receptors
Since the pioneering work by S. M. Reppert and
colleagues, who first cloned amelatonin receptor from
Xenopus melanocytes [64] and who found homologs
in other vertebrate species [65–67], high-affinity
membrane receptors have been studied in detail. In
mammals, two receptors are present,MT1 andMT2 (in
earlier terminology called Mel1a and Mel1b) [66–68].
The original terminology is sometimes maintained in
studies on non-mammalian vertebrates or in compa-
rativework, because a thirdmelatonin receptor type is
present in these organisms [69], Mel1c, to which no
denomination corresponding to MT1 or MT2 is
allowed, for formal reasons of nomenclature. Func-
tionally different isoforms of Mel1c have been descri-
bed, which lead to decreases in cyclic GMP [70]. Mel1c
must not to be confused with a binding site formerly
called MT3, which is an entirely different protein and
not a receptor in the strict sense.
As far as can be judged to date, all chronobiotic
effects, i.e. all actions directly influencing a circadian
master clock, are mediated by the membrane recep-
tors mentioned, in mammals by MT1 and MT2 [67–
69]. In the SCN, melatonin affects, under both in vivo
and in vitro conditions, the phase as well as the
amplitude of the circadian oscillation. Phase shifting is
preferentially exerted via MT2, whereas neuronal
firing is acutely suppressed through MT1 [67, 71, 72].
The two receptor subtypes are complementary in their
actions and can, to a limited extent, mutually sub-
stitute for each other. This seems important insofar as,
exceptionally, a functionally active MT2 (Mel1b) re-
ceptor can be missing, as found in Siberian hamsters,
Phodopus sungorus and P. campbelli [73]. Since the
mammalian pineal gland is under control of the SCN,
the action of melatonin on this circadian pacemaker
represents a feedback mechanism involved in the
readjustment of the oscillator.
In seasonal breeders, high densities of the membrane-
bound receptors are also found in the median
eminence and pars tuberalis. While many earlier
reports deal with binding of 2-[125I]iodomelatonin,
specific MT1 expression was demonstrated in various
species, whereas the evidence for the presence of MT2
is mostly indirect, based on immortalized cell lines or
antagonist experiments [68, 74–76]. Melatonin re-
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ceptors in the median eminence/pituitary system play
a pivotal role in seasonal control, especially of sexual
activity [65, 68, 75, 76]. This includes an influence of
daytime information by regulation of clock genes in
the pars tuberalis [75]. While melatonin regulates the
secretion of hypothalamic and adenohypophyseal
hormones, melatonin receptor expression can also
be subject to control by gonadotrophin-releasing
hormone, at least in a developmental context. De-
pending on vertebrate taxa or species, the effects of
melatonin on reproductive functions are, sometimes,
much more complex and involve actions at various
levels of the hormonal axis, including the gonads [68].
While MT1 and MT2, or – in birds – Mel1c, are highly
expressed in the SCN or in the median eminence/
anterior pituitary system, they are also found –
sometimes in a species-specific manner – in various
other tissues, where they can exert numerous effects,
whichmay be chronobiological in nature, owing to the
cyclicity of circulating melatonin, but not necessarily
chronobiotic, to the extent that master clocks are not
involved. The receptors have been detected in many
tissues, such as retina, other brain areas, choroid
plexus, cerebral and peripheral vasculature, Harder-
ian gland, reproductive organs includingmyometrium
and adrenal cortex [68, 76]. Although expression
levels remained low in some of these tissues, their
ample distribution indicates melatonin responsive-
ness of numerous peripheral organs [76].
The – demonstrated or assumed – functional signifi-
cance of melatonin signaling via membrane receptors
cannot be outlined here in any detail for all these
organs. Instead, with a few selected cases in focus,
signal transduction pathways will be discussed. MT1,
MT2 and likewise Mel1c, are G protein-coupled
receptors [64–66, 68]. Their classic mode of action is
that of a Gi-mediated inhibition of adenylyl cyclase,
resulting in decreases of PKA activity and CREB
phosphorylation. This holds undoubtedly for SCN
neurons, but is, even there, not an exclusive mecha-
nism. As with many other G protein-coupled recep-
tors, the presence ofGprotein subforms in a particular
cell type can substantially change the specific re-
sponse. Co-activation or alternate activation of Go or
Gq has been repeatedly observed [77–79]. In some
cases, including studies in transfected cells, other G
proteins such as Gz or G16 were reported to couple
differentially to melatonin receptors [79–81]. While
coupling to Gi protein subforms causes decreases in
cAMP, rises in cAMP were also described, e.g., for
Mel1c signaling via az coupling to adenylyl cyclase type
II [82]. Gi-dependent mechanisms may affect not only
cAMP levels, but may also modulate, in some cells, K+
conductance, and additionally stimulate, via bg, phos-
pholipase Cb (PLCb), whichmay also be the case with
Go [79]. PLCb activation has been observed in SCN
slices, too [83], but this seems to be a more general
phenomenon of either parallel or alternate melatonin
signaling, observed in various target tissues, involving
either pertussis toxin-sensitive (Gi/Go) or insensitive
(e.g.,Gq)Gproteins [79, 84, 85].Actions via PLCb can
have numerous consequences, from activation of PKC
subforms, CaM kinases, the opening of Ca2+-activated
K+ channels and modulation of various other protein
kinases of the MAP and JNK pathways. However, it
should be emphasized (i) that the signaling mecha-
nisms are strongly cell type-dependent because of
differences in G protein subforms and in coupling of
MT1 orMT2, (ii) that findings obtained in the SCN are
not always applicable to peripheral organs and vice
versa, and (iii) that the signaling via MT1 or MT2 can
even have opposite effects. An impressive example is
vasomotor control by melatonin. While actions via
MT1 cause a pertussis toxin-sensitive vasoconstriction
by opening of BKCa channels, those via MT2 result in
vasodilation [20, 68].
Several melatoninergic agonists and antagonists have
been developed and used as investigative drugs or, in
the case of ramelteon, as an FDA-approved sleeping
pill. For reasons of space, this important aspect cannot
be discussed here in detail.
Other binding sites
In addition to the G protein-coupled receptors, other
binding sites of melatonin exist. Their binding affin-
ities are mostly lower than those of MT1 andMT2, but
could suffice for physiological responses at elevated
concentrations that seem to be present in several
tissues. In at least one case, this extends beyond the
animals, so that high concentrations of melatonin
found in unicells, fungi and some plants may act via
non-membrane binding sites.
One of the melatonin-binding proteins was originally
believed to be anothermembrane receptor andnamed
MT3, but it turned out to be amainly cytosolic enzyme,
quinone reductase 2 (=QR2=NRH:quinone oxido-
ACHTUNGTRENNUNGreductase 2=NQO2; NRH=dihydronicotinamide
riboside) [86–88]. The enzyme is expressed in several
tissues, including the brain [87]. Some of its polymor-
phic subforms have been related to Parkinsons
disease [89]. Disruption of the NQO2 gene leads to
bone marrowmyeloid hyperplasia [90]. This indicates
a role beyond detoxification of xenobiotics. The
frequently proposed assumption of a role in redox
metabolism, eventually in terms of protection, is
actually nothing more than an idea. Even though a
function in ubiquinone reduction has been suggested,
the precise role of this enzyme is not really understood
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[91]. Recently, melatonin was assumed to be a co-
substrate serving as a hydrogen/electron donor to
other redox co-factors such as FAD [92], a concept
still requiring further experimental support. It should
also be noted that NAS has an affinity for NQO2
comparable to that of melatonin [cf. discussion in ref.
20].
A melatonin-binding protein of considerable regula-
tory significance is calmodulin. Its affinity to melato-
nin is sufficient for mediating effects at elevated
physiological concentrations, especially those at-
tained in tissues [93–95]. Melatonin binding results
in inhibitions of CaM kinase II [94] and of neuronal
NO synthase [96]. Moreover, melatonin causes
PKCa-dependent phosphorylation of calmodulin
[97], presumably by signaling mechanisms described
in the preceding section, but this effect is important
insofar as it perpetuates CaM-dependent inhibitions.
Interacting calmodulin and kinase effects are relevant
to rearrangements of the cytoskeleton [95], which
represent some of the earliest effects described for
melatonin, including ciliates and plants [8, 96]. An
additional facette of melatonin/Ca2+ interactions is
the binding to calreticulin, and, perhaps, to two
nuclear proteins, one of which had high homology to
calreticulin, whereas the other was structurally differ-
ent [98].
Nuclear binding sites of melatonin have been amatter
of considerable debate. Meanwhile, many publica-
tions have dealtwith transcription factors belonging to
the retinoic acid receptor superfamily, in particular,
RORa1, RORa2 and RZRb [99–102], and their
classification as nuclear receptors seems justified,
although their affinity to melatonin is lower. A
synthetic ligand, CGP 52608 [99], has been repeatedly
used for identifying effects by these nuclear proteins.
RORa1 and RORa2 seem to be involved in some
aspects of immune modulation, and RZRb is ex-
pressed in the central nervous system, including the
pineal gland [20, 102].Moreover, RORawas assumed
to mediate upregulations of antioxidant enzymes
[101]. Still, the full spectrum and physiological mean-
ing of these receptors remains to be clarified.
A further melatonin binding site seems to exist in rat
brain mitochondria, for which a dissociation constant
of 150 pM and a total number of specific binding sites
of 30 fmol/mg have been determined [20]. The protein
is assumed to be localized at the amphipathic ramp of
complex I in the mitochondrial electron transport
chain. At elevated concentrations, melatonin was also
shown to directly inhibit the opening of the mitochon-
drial permeability transition pore [103], a finding that
would imply an additional, low-affinity mitochondrial
binding site.
Although a considerable amount of clarification is
required concerning the binding sites different from
the G protein-coupled receptors, the findings men-
tioned in this section collectively indicate that mela-
tonin is much more pleiotropic than previously
believed, not only with regard to the numerous target
organs, G proteins and G protein-regulated proteins
involved, but also to additional signaling mechanisms.
Tissue versus circulating melatonin
The consequences of extrapineal melatonin biosyn-
thesis merit particular consideration because they
profoundly change our view of the biological role of
this molecule. Absence of robust melatonin rhythms
or low-amplitude variations imply roles different from
the transmission of dark signals. In tissues containing
considerably higher levels than in the circulation, a
protective role may be assumed. Numerous antiox-
idant, antiinflammatory, antiexcitatory/antiexcitotox-
ic and oncostatic effects have been reported in
countless publications and have been frequently
reviewed [8, 20, 27, 31, 91, 96, 102, 104, 105]. Although
many of these investigations have been conducted at
high doses, they are not collectively physiologically
irrelevant, especially when tissue concentrations are
approaching the micromolar range, or when protec-
tion by melatonin has been demonstrated at levels
found in the circulation [20, 96].
In organs which contain melatonin above plasma
levels, but poorly release the indoleamine, an answer
has to be given as to why melatonin is not – or only in
low quantities – entering the circulation, although it is
usually believed to cross any membrane because of its
amphiphilicity [27, 91, 105]. If tissue concentrations
have been determined correctly, the answer can only
be that of sequestration by non-receptor binding sites
[20]. It cannot be said with certainty whether the
major proteins involved have already been identified,
but the binding to calreticulin [98] and to abundant
nuclear proteins [106] may contribute to melatonin
retention.
Low-amplitude rhythms or absence of (robust)
rhythms in some tissues can resolve another paradox,
namely, why nocturnally peaking melatonin should
exert protective effects in both day- and night-active
animals, whereas reactive oxygen and nitrogen species
are preferentially produced in circadian phases of
motor and neuronal activity. If rhythmicity is poorly
expressed in an organ or almost absent, the circadian
phase loses its relevance for tissuemelatonin, and only
the generation of reactive intermediates becomes
decisive for a phase of detoxification [91, 105].
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High amounts of tissue melatonin – cf. the several
hundred-fold quantities in the gastrointestinal tract
compared to the pineal – has another important
consequence, which is at variance with the frequently
read statement that melatonin is almost quantitatively
metabolized in the liver to 6-hydroxymelatonin, with
subsequent conjugation and excretion as 6-sulfatox-
ymelatonin. This may be true for the circulating
hormone and for single intravenous injections, but has
already turned out to be wrong in the infusion
experiment [28]. Release of non-metabolized mela-
tonin to the intestinal lumen has been shown repeat-
edly [26, 28–30]. With regard to the manyfold higher
quantities outside pineal and circulation, hepatic 6-
hydroxylation as an almost exclusive pathway appears
extremely illogical. That statement also negates long-
known alternate pathways of melatonin metabolism
(Fig. 2), such as demethylation by the P450 isoforms
CYP2C19 and, to a much smaller extent, CYP1A2;
deacetylation by aryl acylamidases, melatonin deace-
tylases or eserine-sensitive acetylcholinesterase, and
pyrrole-ring cleavage [20, 102]. Their relevance in the
central nervous system was recently reviewed [20]. In
the spinal cord, an inhibitory effect of melatonin on
nociceptive transmission was maintained by eserine
[107]. InXenopusmelanophores, a loss of responsive-
ness to melatonin was prevented by the same drug
[108]. Other recent estimations of quantitative mela-
tonin metabolism came to the conclusion that about
one-third of the indoleamine is converted by pyrrole-
ring cleavage to methoxylated kynuramines (Fig. 2)
[109]. The rates may be even higher in some tissues in
which P450 enzymes are poorly expressed [27]. These
kynuramines had already been shown decades ago to
represent major melatonin metabolites in the brain,
whereas no 6-hydroxymelatonin was detected in that
study [22], although 6-hydroxylation should be possi-
ble in the brain because of the presence of CYP1B1
[110] and may have been overlooked at that time.
These findings are of particular importance insofar as
melatonin is released from the pineal gland not only to
the circulation, but also, at much higher concentra-
tions, via the pineal recess into the third ventricle [111,
112]. Since melatonin concentrations in the cerebro-
spinal fluid obtained from lumbal puncture are in the
range of serum levels, most of the compound must
have been either taken up or metabolized by the brain
tissue before entering the spinal cord.
Complexity of metabolism
P450 enzymes are organ specifically expressed and
catalyze hydroxylation or dealkylation. The 6-hydrox-
ylating subforms, CYP1A2, and with smaller contri-
butions, CYP1A1 and CYP1B1 [110], are present in
the liver, but are found in other tissues too. The major
demethylating subform, CYP2C19, is also expressed
in the liver [110]. After oral melatonin administration
to mice, NAS amounted to only about 3% of the
urinary metabolites [113].
Deacetylation to 5-MT leads to another bioactive
molecule. Contrary to melatonin and NAS, this
molecule is a substrate of monoamine oxidase A
(MAO A), and the resulting oxidation product, 5-
methoxyindole-3-acetaldehyde, is converted by alde-
hyde dehydrogenase to 5-MIAA, or by alcohol
dehydrogenase to 5-ML (Fig. 2), two compounds
which are also formed by O-methylation of 5-
hydroxylated analogs [20]. These metabolites are
not restricted to vertebrates, but are also produced
in dinoflagellates and, 5-ML at least, in brown algae,
red algae and yeast [8, 10, 42]. While 5-MIAA seems
to be an end product, which is excreted, 5-ML has
been considered as another bioactive molecule. A
further 5-MT metabolite, the b-carboline pinoline,
known as a psychotropic drug interfering with sero-
tonin availability, will not be discussed here because a
considerable fraction is artificially formed during
extraction.
N,N-dimethyl-5-methoxytryptamine, which is either
produced from 5-MT or by O-methylation of bufote-
nin, has properties of an endogenous hallucinogen
[20].O-acetyl-5-methoxytryptophol, a structural mel-
atonin homolog, is formed from 5-ML in organs
containing high melatonin concentrations, such as the
pineal gland. Several pharmacological effects com-
prise inhibition of nicotinic and muscarinic acetylcho-
line receptors as well as decreases in pituitary
prolactin and luteinizing hormone [20].
The metabolic route of pyrrole-ring cleavage (Fig. 2)
leads to the 5-methoxylated kynuramines, N1-acetyl-
N2-formyl-5-methoxykynuramine (AFMK) and N1-
acetyl-5-methoxykynuramine (AMK). AFMK can be
formed either directly from melatonin or indirectly
from a tricyclic metabolite, cyclic 3-hydroxymelatonin
(c3OHM). c3OHM is a product of melatonin oxida-
tion by free radicals, in particular, by sequential
interactions with two hydroxyl radicals [114, 115]. It
is found in rodent urine after melatonin administra-
tion [113], and is strongly elevated after exposure to
ionizing radiation [114]. It is a remarkable fact that
numerous reactions of melatonin lead to the same
product, AFMK, and that this kynuramine is fre-
quently the major product in various oxidation
systems, especially when they are designed in a way
not to generate a single radical species, but to consider
the physiological prevalence of superoxide anions
[115, 116], which can serve as terminators of radical
reaction chains [8, 115, 116]. The spectrum of reac-
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tions leading to AFMK is exceptional. It comprises
enzymes, such as indoleamine 2,3-dioxygenase or,
quantitatively important, myeloperoxidase [109],
pseudoenzymatic catalysis by hypervalent oxyferryl-
hemoglobin or hemin, and various photochemical and
radical reactions [10, 105, 117].
The quantitative relevance of AFMK and AMK
seems to have been underrated for quite some time.
Apart from the widely neglected demonstration of
these kynuramines as major melatonin metabolites in
the brain [22], it may be amisconception to judge their
significance on the basis of urinary or plasma concen-
trations. Only small amounts of AFMK and AMK
were found in the urine upon oral administration of
melatonin [113], but, in stark contrast, high quantities
were found after injection into the cisterna magna
[22]. The low urinary quantities detected in some
experiments or in untreated animals should be seen in
relation to administration routes, formation in tissues
and the metabolic fate of the kynuramines, which may
not become apparent in body fluids. High concen-
trations of AFMK have been found in HaCaT
keratinocytes [36]. One might also note high amounts
and circadian rhythmicity of AFMK found in a plant,
the water hyacinth, Eichhornia crassipes [118]. At
lower physiological concentrations of melatonin, the
role of its oxidation by free radicals may largely be
seen in the formation of AFMK and its secondary
metabolites [91, 105].
Other products deriving from melatonin by radical
reactions are hydroxylated indoles, whereas dimers
are relatively rare because of the methoxy group,
which largely prevents the formation of O-centered
and C-centered indolyl radicals [22, 105]. Preferential
Figure 2. The complexity of mel-
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have been identified as AFMK
metabolites and chemically char-
acterized [123]. Additional reac-
tions and metabolites, which also
exist, have not been included.
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sites of hydroxylations have been identified [119].
Apart from c3OHM, 6-hydroxy- and 2-hydroxymela-
tonin can be formed, the latter being in equilibrium
with its tautomer, N-acetyl-5-methoxy-2-indolinone
[120].
Deformylation of AFMK toAMK is catalyzed by two
enzymes, arylamine formamidase [27, 102, 105] and
hemoperoxidase (catalase) [105, 121]. Recently,
another photochemical mechanism by UV light
(Fig. 2) has been described [122]. AMK formation
may not be an exclusive route of AFMK metabolism,
since free-radical reactions also led to a couple of C2-
substituted 3-indolinones (Fig. 2), representing a
novel class of oxidation products [123].
While AMK was regarded for decades as an end
product because of its appearance in the urine, this
seems rather unlikely, since AMK was shown to be
easily oxidized [124] and to readily interact with
reactive nitrogen species. Even the dry solid forms
new products with trace gases present in the air, when
exposed on the large surface of a silica gel. Two
products are formed in solution by reactive inter-
mediates present in biological material, a nitrosated
derivative, 3-acetamidomethyl-6-methoxycinnolinone
(AMMC) (Fig. 2), and a nitrated compound, N1-
acetyl-5-methoxy-3-nitrokynuramine (AMNK=3-
nitro-AMK) [125]. AMMC is generated by all three
different NO congeners, ·NO, NO+ and HNO, al-
though the reaction with NO+ is physiologically less
likely, because of the short half-life of the cation in
aqueous solution at pH 7.4 [126]. AMMC represents a
stable compound, contrary to the majority of otherN-
nitrosated substances [127], includingN-nitrosomela-
tonin, which easily redonateNO.AMNKwas found to
be produced by the combination of peroxynitrite and
CO2, a physiological nitrating mixture leading to
carbonate radicals (CO3·
) and ·NO2 [125].
The non-classic actions of melatonin
Countless publications have dealt with protective
actions of melatonin. Although the number of such
reports is meanwhile higher than that on its chrono-
biological role, the understanding in mechanistic
terms still awaits further deepening under many
aspects. Nevertheless, the high potential of such a
function seems worthy of considerable efforts.
Melatonin participates in various lines of defense. A
first one is that of antioxidative protection, a phenom-
enon which has been frequently reviewed [e.g., 8, 27,
91, 96, 101, 102, 104, 105, 119, 121] and will be
discussed here only in its general traits. Investigation
of the antioxidant actions of melatonin was strongly
stimulated by the finding of potent direct scavenging
of hydroxyl radicals by this indoleamine [128]. How-
ever, antioxidative protection has turned out to be
more than radical scavenging. Under physiological
conditions, the capability of donating electrons to free
radicals –which is present in thismoleculewithout any
doubt – may have other biological meanings than to
detoxify a certain number of free radicals, already
from the viewpoint of stoichiometry. At pharmaco-
logical concentrations, the value of melatonin as a
direct scavenger has been repeatedly demonstrated
(cf. reviews mentioned). Certain cells or organisms
containing melatonin concentrations in the (some-
times upper) micromolar range may also profit by
direct scavenging. Additional roles may be sought in
the non-enzymatic formation of other bioactive com-
pounds and in the capability of undergoing reactions
with electron exchanging or transporting systems,
such as the respiratory chain [91, 105]. Upregulation
of antioxidant and downregulation of – a few –
prooxidant enzymes [91, 104, 105] certainly contrib-
utes to the antioxidant balance, but these effects
should not be generally overrated. Induction of
hemoperoxidase (catalase), superoxide dismutase
subforms, glucose-6-phosphate dehydrogenase and
g-glutamylcysteine synthase are organ-specific, and
the meaning of upregulations of just a few percent,
sometimes only demonstrated at the mRNA level, is
questionable. Amost frequently reported and reliable
effect is the stimulation of glutathione peroxidase, as
particularly found in the central nervous system. The
cellular mechanism of upregulation has only been
tentatively addressed [101], but is not really elucidat-
ed in its details.
Since detoxification of free radicals and other oxi-
dants did not fully explain the antioxidative efficacy of
melatonin, radical avoidance was brought into focus
[27, 91, 105]. Formation of reactive oxygen and
nitrogen species can be reduced by several actions of
melatonin. First, appropriate timing and coordination
of rhythms, as favored by the indoleamine, should
diminish oxidative stress, because oxidative damage
was elevated in the clock mutants, per0 and pers in
Drosophila, tau in Syrian hamster [91]. Second, the
antiexcitatory/antiexcitotoxic effects of melatonin
should reduce radical formation as well, by attenuat-
ing their metabolism-related generation and the
prevention of Ca2+- and NO-dependent cellular stress
[91, 105]. In this context, mitochondria seem to be a
particular target. These organelles represent in many
cells a major source of superoxide anions, due to
electron leakage, especially from complexes I and III
of the electron transport chain, radicals which are not
quantitatively eliminated by mitochondrial and cyto-
solic superoxide dismutases (MnSOD and Cu,Zn-
SOD). Superoxide anions are sources of peroxynitrite
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from cytosolic or mitochondrially generated NO and
lead, via combination with CO2 or protons, to
carbonate (CO3·
), hydroxyl (·OH) and ·NO2 radicals.
H2O2 formed by the SODs is a source of hydroxyl
radicals. Electron overflow at the iron-sulfur cluster
N2 of complex I, i.e., at the bottleneck of the transport
chain, seems to be an important cause of enhanced
superoxide generation. This site is assumed to be
modulated by melatonin [27, 91, 105] and may be
associated with a mitochondrial high-affinity binding
site [20] (cf. section on Other binding sites). Although
many details of this concept of mitochondrial radical
avoidance remain to be elucidated, pertinent effects of
melatonin at the level of this organelle have been
repeatedly described, such as support of mitochon-
drial electron flux, stimulation of complex I and IV
activities, prevention of mitochondrial calcium over-
load and maintenance of mitochondrial membrane
potential and of ATP formation [91, 105, 129, 130].
These findings gain particular significance because of
normalizations in mitochondrial functions achieved
by melatonin in senescence-accelerated mice [131,
132].
Mitochondrial hypoactivity and dysfunction are phe-
nomena associatedwith aging, but also with numerous
diseases. These organelles also play a pivotal role in
the induction of apoptosis. Melatonin has been
frequently shown to antagonize or prevent apoptosis
by modulating mitochondrial functions [133, 134],
including effects on calcium homeostasis and mito-
chondrial membrane potential [105, 134, 135], and
also by directly inhibiting the mitochondrial perme-
ability transition pore [103].
Antiexcitatory and antiexcitotoxic effects are partially
related to mitochondria, in terms of avoidance of
calcium overload and elevated radical formation in
these organelles. These actions, which extend to
anticonvulsant and anxiolytic properties [102], go
beyond the chronobiotic and sleep-inducing actions
and, again, are highly complex. In mammals, modu-
lations ofGABAand glutamate signaling are involved
and include secondary effects through decreases in
cytosolic Ca2+ via GABAc [136] or metabotropic
mGlu3 receptors [137], interferencewith neuronalNO
synthase, directly, or indirectly by AMK [102, 104
105], effects on K+ currents, as studied in the
cerebellum [138], and potentiation of strychnine-
sensitive glycine-induced currents [139].
Immunomodulation by melatonin represents another
line of defense. This includes antiiflammatory proper-
ties of the indoleamine, in which antioxidant, NO-
attenuating, and mitochondrial effects act in concert
with the attenuation of proinflammatory signaling.
Moreover, melatonin is produced by various leuko-
cytes, such as monocytes, eosinophils, mast cells,
natural killer (NK) cells and several leukocyte-de-
rived cell lines [37, 40, 140]. It was also found in
thymocytes and epithelial cells [40], but the origin is
not clear in these cases. Immunomodulation by
melatonin has recently been reviewed several times
[e.g. , 40, 102, 131, 132]. Main findings are the
activation of various cell types, such as T, B and NK
cells, monocytes and splenocytes, and modulation of
cytokine release.Melatonin was shown to enhance the
production of interleukin (IL)-2, IL-6 and IL-12,
whereas levels of interferon-8 or tumor necrosis-
factor-a were sometimes decreased but in other cases
increased [40, 143]. Melatonin also counteracted
inhibitory effects of PGE2 on IL-2 production [68,
144]. With regard to the complexity of the immune
system, some divergence in effects depending on cell
types, differentiation state and mixtures of cells in test
systems should not be surprising. In the immune
system, different melatonin receptors are involved.
MT1was found tomediate effects concerning IL-2, but
the presence of this receptor was demonstrated in
numerous leukocyte subtypes [40, 68]. Signaling via
MT2 was, e.g. shown to stimulate splenocyte prolifer-
ation and to decrease leukocyte rolling [68, 145]. In
avian splenocytes, growth stimulation is mediated by
the Mel1c receptor [146]. Based on pharmacological
criteria, inhibition of leukotriene B4-induced endo-
thelial leukocyte adhesion was ascribed to the binding
site previously named MT3 [145], now known to be
quinone reductase 2, but, in the absence of demon-
strated signaling pathways, this should be judged with
caution. Expression of ROR and RZR subforms has
been reported for various leukocytes and related cells
such as splenocytes, thymocytes and Jurkat cells, and
some of the actions of melatonin seem to be mediated
by these transcription factors [100, 141, 142, 147].
High densities of nuclear binding sites, as sometimes
observed, should not be immediately taken as a sign
for involvement of ROR/RZR receptors, because of
other nuclear binding proteins [98, 106]. Inmelatonin-
synthesizing leukocytes, concentrations may be suffi-
cient for nuclear receptors and mediate autocrine
effects. The interplay of membrane and nuclear
receptors in the immune system remains an intriguing
field.
Actions of metabolites
Melatonin may also be regarded as a prodrug leading
to other bioactivemolecules [27]. Earlier studies were
mostly oriented at actions already known from
melatonin, with the frequent outcome that the metab-
olites were only effective at higher concentrations
[20]. Substances like 5-MT and NAS, being both
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metabolites and precursors, possess high affinities for
some 5-HT receptor subforms found in both the
central nervous system and the periphery [reviewed in
ref. 20]. It is, however, difficult to judge a putative role
of these compounds as secondary mediators of
melatonin in the CNS, in part because of concentra-
tions, especially in the case of the easilymetabolized 5-
MT, and because NAS is apparently formed without
being converted to melatonin and exerts independent
actions. The actions of 5-MT in brain and retina have
been recently reviewed [20]. More detailed informa-
tion on profound and ecophysiologically relevant
actions by 5-MT in dinoflagellates can be found
elsewhere [10, 42].
Actions of non-indolic metabolites have only been
decribed for mammals, except for some unpublished,
preliminary data on life extension by AFMK in a
rotifer, Philodina acuticornis [B. Poeggeler, personal
communication]. In the first decades after discovery
of AFMK and AMK, some effects were described
concerning prolactin release, retardation of testicular
growth, binding to benzodiazepine and melatonin
receptors [summarized in ref. 148]. Binding affinities
were not sufficient to explain actions of the indole-
amine by conversion toAFMKorAMK.However, an
interesting chronobiological effect of AFMK was
described, which was, unfortunately, never followed
up in other comparable systems. In rats, AFMK was
shown to promote the re-entrainment of the melato-
nin rhythm [149]. In the taxonomically very distant
Lingulodinium, no phase shifting by AFMK was
observed [R. Hardeland, unpublished data]. How-
ever, the life cycles of malaria parasites (Plasmodium
chabaudi and Plasmodium falciparum) were
synchronized by AFMK in the upper nanomolar
range, an effect which was associated with rises in
cytosolic calcium and which was blocked by luzindole
[150], otherwise being an MT1/MT2 melatonin recep-
tor antagonist. The inhibition by luzindole may raise
questions concerning conclusions on melatonin sig-
naling via MT1 and/or MT2 in other cases, or on a
cryptic, perhaps indirect action of AFMK at these
receptors.
AMK was shown to efficiently inhibit prostaglandin
synthesis [151], a property of, perhaps, considerable
pharmacological interest. At the time of discovery,
cyclooxygenases (COX) 1 and 2 were not distinguish-
ed, but the efficacy of AMK was reported to be far
higher than that of acetylsalicylic acid (aspirin).
Recently, AMK was reported to downregulate
COX-2 – but not COX-1 – expression inmacrophages,
an effect shared by its precursors AFMK and mela-
tonin [152]. Whether antiinflammatory or other
immunological actions by 5-methoxylated kynura-
mines may be of medicinal relevance, remains to be
studied. In cases of viral meningitis, considerably
enhanced levels of AFMK in the cerebrospinal fluid
correlated with inflammatory markers such as tumor
necrosis factor-a, IL-8 and IL-1b [153]. This may only
reflect rises in cerebral melatonin oxidation. How-
ever, AFMK was also reported to be a more efficient
inhibitor of lipopolysaccharide (LPS)-induced pro-
duction of TNF-a and IL-8 in neutrophils, compared
to melatonin [154], an effect which cannot be ex-
plained by affinity or selectivity to free radicals
released in response to LPS.
AFMKwas also used to antagonize oxidative stress, at
pharmacological concentrations. It was shown to
protect DNA from oxidative damage by hydroxyl
radicals generated by a chromium(III)-based Fenton-
analog reaction [155], or by a d-aminolevulinic acid/
Fe2+ system [156], but it remained less efficient than
melatonin. This is not surprising because AFMK
exhibits a preference for two-electron transfer reac-
tions [117] and is, therefore, a poorer radical scavenger
thanmelatonin or its deformylated metabolite, AMK,
which easily undergoes single-electron transfer reac-
tions [105, 124]. Thus, protective effects by AFMK
observed in living cells, such as inhibition of toxicity by
glutamate, H2O2, or amyloid b25–35 peptide in hippo-
campal neurons [117], might be the consequence of its
conversion to AMK. The same may hold for protec-
tion against oxidative damage to DNA, proteins and
lipids by X-rays [157]. Protective actions by AMK are
more than just radical scavenging, because of addi-
tional effects already found at very low, nanomolar or
even lower concentrations. Support of mitochondrial
functions was observed in the nanomolar range [130].
AMK, being an amphiphilic compound with a slightly
higher lipophilicity than melatonin, has been suggest-
ed to participate in an electron shuttle, which may
bridge bottlenecks in the electron transport chain and,
thereby, diminish electron leakage [91, 105]. Atten-
tion may also be directed to the structural similarities
between ubiquinones and AMK [91]. Moreover,
AMK was shown to be a highly efficient inhibitor of
neuronal NO synthase, with an IC50 in the nanomolar
range, but demonstrable efficacy already at 1011 M
[158].
With regard to specific actions of kynuramines, it
should be remembered that this chemical family
represents its own, though frequently forgotten, class
of biogenic amines, including 5-hydroxylated, C5-
unsubstituted, and N,N-dimethylated compounds, for
which various effects have been described [148].
Other products from the kynuric pathway of melato-
nin metabolism may additionally contribute to a
complex action spectum. The group of cinnolines, to
which AMMC belongs, contains pharmacologically
active compounds, which have been used as medica-
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ments or investigative drugs, because of their anti-
allergic, antitumor, anxiolytic and other neurotropic
properties [125].
Conclusions
The diversity of melatonin actions, the number of
demonstrated or putative binding sites, differential G
protein coupling, the existence of numerous target
cells and organs, pineal and extrapineal formation and
the possibility of additional actions by its metabolites
demonstrate an exceptional pleiotropy. This may
reflect an orchestrating function, butmay also become
a problem when specific actions are desired, in terms
of both experimental and applied approaches. In
practice, multiple effects can hardly be avoided.
Whether they are really disadvantagous for a treated
organism, or dangerous, remains to be studied.
As a substance found in numerous phylogenetically
very distant organisms, at levels differing considerably
from taxa to taxa, a uniform spectrum of actions
should not be expected, although some themes, such
as calmodulin signaling or antioxidant actions, may go
across the multitude of species synthesizing this
indoleamine. Various findings indicate that it is not
generally a compound found only in traces – as in the
circulation. Micromolar levels can be present outside
the vertebrates, and some findings indicate that tissue
melatonin may be sometimes much higher than the
blood level. Additional complexity results from differ-
ent sites of formation in a vertebrate body, which,
again, exceeds the classic sites of biosynthesis. The
consequences of tissuemelatonin and its different fate
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not only and primarily be determined in body fluids
but rather in tissues, and differences in administration
routes deserve particular consideration.
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